Thrombosis Risk with Transcatheter Aortic Valve Replacement

References

• Faggiano P, Antonini-Canterin F, Baldessin F, Lorusso R, D’Aloia a, Cas LD. Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovascular Ultrasound. 2006;4(1):27. doi:10.1186/1476-7120-4-27.
   Google Scholar
• Iung B, Cachier a, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005;26(24):2714–2720. doi:10.1093/eurheartj/ehi471.
   PubMed Web of Science ®Google Scholar
• Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J. 2018;39(28):2635–2642. doi:10.1093/eurheartj/ehy107.
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–1607. doi:10.1056/NEJMoa1008232.
   PubMed Web of Science ®Google Scholar
• Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187–2198. doi:10.1056/NEJMoa1103510.
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609–1620. doi:10.1056/NEJMoa1514616.
   PubMed Web of Science ®Google Scholar
• Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376(14):1321–1331. doi:10.1056/NEJMoa1700456.
   PubMed Web of Science ®Google Scholar
• Baumgartner H, Falk V, Bax JJ, et al. ESC/EACTS guidelines for the management of valvular heart disease the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) document review. Thierry Folliguet. 2017;1. doi:10.1093/eurheartj/ehx391.
   Google Scholar
• Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(25). doi:10.1161/CIR.0000000000000503.
   Web of Science ®Google Scholar
• Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–1705. doi:10.1056/NEJMoa1814052.
   PubMed Web of Science ®Google Scholar
• Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–1715. doi:10.1056/NEJMoa1816885.
   PubMed Web of Science ®Google Scholar
• Nalluri N, Atti V, Munir AB, et al. Valve in valve transcatheter aortic valve implantation (ViV-TAVI) versus redo-surgical aortic valve replacement (redo-SAVR): a systematic review and meta-analysis. J Interv Cardiol. 2018;31(5):661–671. doi:10.1111/joic.12520.
   PubMed Web of Science ®Google Scholar
• Hellhammer K, Piayda K, Afzal S, et al. The latest evolution of the Medtronic Corevalve system in the era of transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11(22):2314–2322. doi:10.1016/j.jcin.2018.07.023.
   PubMed Web of Science ®Google Scholar
• Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials. J Am Coll Cardiol. 2011;57(3):253–269. doi:10.1016/j.jacc.2010.12.005.
   PubMed Web of Science ®Google Scholar
• Généreux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions. J Am Coll Cardiol. 2012;59(25):2317–2326. doi:10.1016/j.jacc.2012.02.022.
   PubMed Web of Science ®Google Scholar
• Kleiman NS, Maini BJ, Reardon MJ, et al. Neurological events following transcatheter aortic valve replacement and their predictors. Circ Cardiovasc Interv. 2016;9(9). doi:10.1161/CIRCINTERVENTIONS.115.003551.
   Web of Science ®Google Scholar
• Tay ELW, Gurvitch R, Wijesinghe N, et al. A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2011;4(12):1290–1297. doi:10.1016/j.jcin.2011.08.012.
   PubMed Web of Science ®Google Scholar
• Jochheim D, Zadrozny M, Ricard I, et al. Predictors of cerebrovascular events at mid-term after transcatheter aortic valve implantation – results from EVERY-TAVI registry. Int J Cardiol. 2017;244:106–111. doi:10.1016/j.ijcard.2017.03.003.
   PubMed Web of Science ®Google Scholar
• Kapadia S, Agarwal S, Miller DC, et al. Insights into timing, risk factors, and outcomes of stroke and transient ischemic attack after transcatheter aortic valve replacement in the PARTNER trial (Placement of aortic transcatheter valves). Circ Cardiovasc Interv. 2016;9(9):9.doi:10.1161/CIRCINTERVENTIONS.115.002981.
   Web of Science ®Google Scholar
• Nombela-Franco L, Webb J, de Jaegere P, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation. 2012;126(25):3041–3053.doi:10.1161/CIRCULATIONAHA.112.110981.
   PubMed Web of Science ®Google Scholar
• Omran H, Schmidt H, Hackenbroch M, et al. Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study. Lancet. 2003;361(9365):1241–1246. doi:10.1016/S0140-6736(03)12978-9.
   PubMed Web of Science ®Google Scholar
• Bijuklic K, Haselbach T, Witt J, et al. Increased risk of cerebral embolization after implantation of a balloon-expandable aortic valve without prior balloon valvuloplasty. JACC Cardiovasc Interv. 2015;8(12):1608–1613.
   PubMed Web of Science ®Google Scholar
• Van Mieghem NM, El Faquir N, Rahhab Z, et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2015;8(5):718–724. doi:10.1016/j.jcin.2015.01.020.
   PubMed Web of Science ®Google Scholar
• Eggebrecht H, Schmermund a, Voigtländer T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention. 2012;8(1):129–138. doi:10.4244/EIJV8I1A20.
   PubMed Web of Science ®Google Scholar
• Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol. 2017;69(4):367–377. doi:10.1016/j.jacc.2016.10.023.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68(24):2670–2689. doi:10.1016/j.jacc.2016.09.958.
   PubMed Web of Science ®Google Scholar
• Mylotte D, Andalib a, Theriault-Lauzier P, et al. Transcatheter heart valve failure: a systematic review. Eur Heart J. 2015;36(21):1306–1327. doi:10.1093/eurheartj/ehu388.
   PubMed Web of Science ®Google Scholar
• Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389(10087):2383–2392. doi:10.1016/S0140-6736(17)30757-2.
   PubMed Web of Science ®Google Scholar
• Salemi a, Sedrakyan a, Mao J, et al. Individual operator experience and outcomes in transcatheter aortic valve replacement. JACC Cardiovasc Interv. December 2018;4111. doi:10.1016/j.jcin.2018.10.030.
   Google Scholar
• van Wiechen MP, Van Mieghem NM. Maturation from COREVALVE ® to Evolut Pro ®: a clinical overview. Future Cardiol. 2019;15(1):1–8. doi:10.2217/fca-2018-0064.
   Web of Science ®Google Scholar
• Landes U, Bental T, Barsheshet a, et al. Comparative matched outcome of Evolut-R vs Corevalve transcatheter aortic valve implantation. J Invasive Cardiol. 2017;29(2):69–74.
   Web of Science ®Google Scholar
• Forrest JK, Mangi AA, Popma JJ, et al. Early outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Interv. 2018;11(2):160–168. doi:10.1016/j.jcin.2017.10.014.
   PubMed Web of Science ®Google Scholar
• Linke a, Wenaweser P, Gerckens U, et al. Treatment of aortic stenosis with a self-expanding transcatheter valve: the international multi-centre ADVANCE study. Eur Hear J Adv Access. 2014;6. doi:10.1093/eurheartj/ehu162.
   Google Scholar
• Corcione N, Biondi-Zoccai G, Ferraro P, et al. Long-term follow-up of transcatheter aortic valve implantation with portico versus Evolut devices. Am J Cardiol. 2020;125:8. doi:10.1016/J.AMJCARD.2020.01.018.
   Web of Science ®Google Scholar
• Mas-Peiro S, Seppelt P, Weiler H, et al. A direct comparison of self-expandable portico versus balloon-expandable Sapien 3 devices for transcatheter aortic valve replacement: a case-matched cohort study. J Invasive Cardiol. 2019;31(7). E199–E204.
   PubMed Web of Science ®Google Scholar
• Reardon MJ, Feldman TE, Meduri CU, et al. Two-year outcomes after transcatheter aortic valve replacement with mechanical vs self-expanding valves. JAMA Cardiol. 2019;4(3):223. doi:10.1001/jamacardio.2019.0091.
   Web of Science ®Google Scholar
• Vora AN, Dai D, Matsuoka R, et al. Incidence, management, and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11(17):1746–1756. doi:10.1016/j.jcin.2018.05.042.
   Web of Science ®Google Scholar
• Jørgensen TH, Thyregod HGH, Tarp JB, Svendsen JH, Søndergaard L. Temporal changes of new-onset atrial fibrillation in patients randomized to surgical or transcatheter aortic valve replacement. Int J Cardiol. 2017;234:16–21. doi:10.1016/j.ijcard.2017.02.098.
   PubMed Web of Science ®Google Scholar
• Hansson NC, Grove EL, Andersen HR, et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016;68(19):2059–2069. doi:10.1016/J.JACC.2016.08.010.
   PubMed Web of Science ®Google Scholar
• Yanagisawa R, Hayashida K, Yamada Y, et al. Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR. JACC Cardiovasc Imaging. 2017;10(1):1–11. doi:10.1016/j.jcmg.2016.11.005.
   Web of Science ®Google Scholar
• Mangione FM, Jatene T, Gonçalves a, et al. Leaflet thrombosis in surgically explanted or post-mortem TAVR valves. JACC Cardiovasc Imaging. 2017;10(1):82–85. doi:10.1016/j.jcmg.2016.11.009.
   Web of Science ®Google Scholar
• Nijenhuis VJ, Brouwer J, Søndergaard L, Collet J-P, Grove EL, Ten Berg JM. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Heart. 2019;105(10):742–748. doi:10.1136/heartjnl-2018-314313.
   Web of Science ®Google Scholar
• Sellers SL, Turner CT, Sathananthan J, et al. Transcatheter aortic heart valves: histological analysis providing insight to leaflet thickening and structural valve degeneration. JACC Cardiovasc Imaging. 2019;12(1):135–145. doi:10.1016/j.jcmg.2018.06.028.
   PubMed Web of Science ®Google Scholar
• Ruile P, Jander N, Blanke P, et al. Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation. Clin Res Cardiol. 2017;106(2):85–95. doi:10.1007/s00392-016-1052-3.
   PubMed Web of Science ®Google Scholar
• Overtchouk P, Guedeney P, Rouanet S, et al. Long-term mortality and early valve dysfunction according to anticoagulation use. J Am Coll Cardiol. 2019;73(1):13–21. doi:10.1016/j.jacc.2018.08.1045.
   PubMed Web of Science ®Google Scholar
• Yanagisawa R, Tanaka M, Yashima F, et al. Early and late leaflet thrombosis after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2019;12:2. doi:10.1161/CIRCINTERVENTIONS.118.007349.
   Web of Science ®Google Scholar
• Kalra a, Raza S, Puri R, et al. Subclinical leaflet thrombosis and clinical outcomes after TAVR: a systematic review and meta-analysis. Struct Heart. 2018;2(3):223–228. doi:10.1080/24748706.2018.1440678.
   Google Scholar
• Makkar R. PARTNER 3 low-risk computed tomography substudy: subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves. In: Tct 2019. San Fancisco CA; 2019. https://www.tctmd.com/slide/partner-3-low-risk-computed-tomography-substudy-subclinical-leaflet-thrombosis-transcatheter.
   Google Scholar
• De Backer O, Dangas GD, Jilaihawi H, et al. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med. 2019;NEJMoa1911426. doi:10.1056/NEJMoa1911426.
   Web of Science ®Google Scholar
• Yoon S, Bleiziffer S, De Backer O, et al. Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol. 2017;69:21. doi:10.1016/J.JACC.2017.03.017.
   Google Scholar
• Makkar RR, Yoon S-H, Leon MB, et al. Association between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke. JAMA. 2019;321(22):2193. doi:10.1001/jama.2019.7108.
   PubMed Web of Science ®Google Scholar
• Halim SA, Edwards FH, Dai D, et al. Outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valve disease. Circulation. 2020;141(13):1071–1079. doi:10.1161/CIRCULATIONAHA.119.040333.
   PubMed Web of Science ®Google Scholar
• Ueshima D, Fovino LN, Brener SJ, et al. Transcatheter aortic valve replacement for bicuspid aortic valve stenosis with first- and new-generation bioprostheses: a systematic review and meta-analysis. Int J Cardiol. 2020;298:76–82. doi:10.1016/J.IJCARD.2019.09.003.
   PubMed Web of Science ®Google Scholar
• Eitan a, Brinkmann C, Haselbach T, Witt J, Schofer J. Does valve in valve TAVR carry a higher risk for thromboembolic events compared to native valve TAVR? Catheter Cardiovasc Interv. 2020;95(5):1017–1021. doi:10.1002/ccd.28391.
   Web of Science ®Google Scholar
• Malik AH, Yandrapalli S, Zaid S, et al. Valve-in-valve transcatheter implantation versus redo surgical aortic valve replacement. Am J Cardiol. 2020;125(9):1378–1384. doi:10.1016/J.AMJCARD.2020.02.005.
   Web of Science ®Google Scholar
• Nijenhuis V, Ten Berg J, Hengstenberg C, et al. Usefulness of clopidogrel loading in patients who underwent transcatheter aortic valve implantation (from the BRAVO-3 randomized trial). Am J Cardiol. 2019;123:9. doi:10.1016/J.AMJCARD.2019.01.049.
   Web of Science ®Google Scholar
• Rodés-Cabau J, J-B M, RC W, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve. JACC Cardiovasc Interv. 2017;10(13):1357–1365. doi:10.1016/j.jcin.2017.04.014.
   PubMed Web of Science ®Google Scholar
• Mangieri a, Jabbour RJ, Montalto C, et al. Single-antiplatelet therapy in patients with contraindication to dual-antiplatelet therapy after transcatheter aortic valve implantation. Am J Cardiol. 2017;119(7):1088–1093. doi:10.1016/j.amjcard.2016.11.065.
   Web of Science ®Google Scholar
• Hassell MECJ, Hildick-Smith D, Durand E, et al. Antiplatelet therapy following transcatheter aortic valve implantation. Heart. 2015;101(14):1118–1125. doi:10.1136/heartjnl-2014-307053.
   Web of Science ®Google Scholar
• Dangas G, Lefèvre T, Kupatt C, et al. Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: the randomized BRAVO-3 trial. J Am Coll Cardiol. 2015;66:25. doi:10.1016/J.JACC.2015.10.003.
   Web of Science ®Google Scholar
• Ruile P, Jander N, Blanke P, et al. Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation. Clin Res Cardiol. 2017;106(2):85–95. doi:10.1007/s00392-016-1052-3.
   PubMed Web of Science ®Google Scholar
• Banerjee K, Poddar K, Mick S, et al. Meta-analysis of usefulness of anticoagulation after transcatheter aortic valve implantation. Am J Cardiol. 2017;120:1612–1617. doi:10.1016/j.amjcard.2017.07.059.
   Web of Science ®Google Scholar
• Geis N, Kiriakou C, Chorianopoulos E, Pleger S, Katus H, Bekeredjian R. Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2017;12(17):2058–2066. doi:10.4244/EIJ-D-15-00259.
   Web of Science ®Google Scholar
• Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2016. doi:10.1016/j.jcin.2016.06.025.
   Web of Science ®Google Scholar
• Windecker S, Tijssen J, Giustino G, et al. Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study. Am Heart J. 2017;184:81–87. doi:10.1016/j.ahj.2016.10.017.
   PubMed Web of Science ®Google Scholar
• Cooper T. Rivaroxaban (Xarelto): increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement in a prematurely stopped clinical trial; 2018. https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information—xarelto-(rivaroxaban)-(oct-2018).pdf?sfvrsn=0.
   Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa1009638.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Berti S, Cequier a, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am Heart J. 2018;200:44–50. doi:10.1016/j.ahj.2018.03.008.
   PubMed Web of Science ®Google Scholar
• Van Mieghem NM, Unverdorben M, Valgimigli M, et al. Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation in atrial fibrillation – rationale and design of the ENVISAGE-TAVI AF trial. Am Heart J. 2018;205:63–69. doi:10.1016/j.ahj.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;382(18):1696–1707. doi:10.1056/NEJMoa1915152.
   PubMed Web of Science ®Google Scholar